Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading PTN News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.31%165.221.3%$782.35m
GILDGilead Sciences, Inc.
-0.06%67.061.0%$564.12m
INCYIncyte Corporation
0.02%139.514.3%$556.22m
CELGCelgene Corporation
0.00%124.431.1%$495.09m
BIIBBiogen Inc.
-0.44%272.901.3%$436.77m
REGNRegeneron Pharmaceuticals, Inc.
0.14%383.102.1%$349.89m
KITEKite Pharma, Inc.
0.00%78.6117.5%$217.46m
ALXNAlexion Pharmaceuticals, Inc.
0.00%118.531.6%$201.95m
TSROTESARO, Inc.
-0.58%154.0015.6%$192.28m
ILMNIllumina, Inc.
-0.47%170.003.4%$168.21m
VRTXVertex Pharmaceuticals Incorporated
19.85%107.472.0%$160.67m
ESPREsperion Therapeutics, Inc.
1.96%36.3617.7%$152.95m
CLVSClovis Oncology, Inc.
0.00%67.0617.2%$140.22m
AUPHAurinia Pharmaceuticals Inc.
0.70%7.218.0%$131.34m
EXELExelixis, Inc.
0.00%21.285.7%$104.55m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.